AI Article Synopsis
- A patient with advanced neuroendocrine prostate cancer received multiple previous treatments before being part of a Phase II clinical trial.
- The patient was treated with RRx-001, a dual inhibitor targeting CD-47 and SIRP-α.
- After undergoing platinum-based chemotherapy, the patient achieved a complete metabolic response, indicating significant improvement in their condition.
Article Abstract
Presented herein is the case of a heavily pretreated patient with high-grade neuroendocrine prostate cancer that achieved a complete metabolic response on platinum-based chemotherapy after treatment with the dual CD-47 and SIRP-α inhibitor, RRx-001, in a Phase II clinical trial.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6293266 | PMC |
| http://dx.doi.org/10.1002/ccr3.1880 | DOI Listing |
Publication Analysis
Top Keywords
complete metabolic
8
metabolic response
8
response metastatic
4
metastatic castration-resistant
4
castration-resistant neuroendocrine
4
neuroendocrine carcinoma
4
carcinoma prostate
4
prostate treatment
4
treatment rrx-001
4
rrx-001 reintroduced
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!